Medical Weight Loss
Medical weight loss offers an effective approach to achieve significant, sustainable weight loss without surgery.
Take a Closer Look
Tirzepatide (Mounjaro, Zepbound)
Tirzepatide is a newer medication that targets both the GLP-1 and GIP receptors, providing a dual effect that enhances weight loss. Initially approved for diabetes management, Tirzepatide has shown significant weight loss outcomes even among non-diabetic patients.
Studies reveal that patients using Tirzepatide can achieve weight loss of up to 20% of their body weight, which is a remarkable improvement over single-agonist treatments. Tirzepatide’s dual action not only helps reduce appetite and caloric intake but also has unique effects on fat metabolism, offering an exciting new option for medical weight loss.
Semaglutide (Ozempic, Wegovy)
Semaglutide is a GLP-1 receptor agonist that has shown impressive results for weight loss. Originally developed to treat diabetes, it’s now FDA-approved for chronic weight management at a higher dose under the brand name Wegovy®.
Semaglutide works by mimicking the hormone GLP-1, which helps reduce appetite and slow stomach emptying, promoting earlier satiety and reduced calorie intake. In clinical trials, patients on Semaglutide lost an average of 15-18% of their body weight over approximately 68 weeks when combined with lifestyle changes, making it a powerful tool in medical weight management.